<DOC>
	<DOCNO>NCT00697463</DOCNO>
	<brief_summary>Idiopathic osteoporosis ( IOP ) uncommon disorder otherwise healthy young individual sustain one low-trauma fracture . Teriparatide [ PTH ( 1-34 ) ] , FDA approve treatment osteoporosis men postmenopausal woman , work stimulate bone formation . We hypothesize teriparatide significantly increase bone density ( BMD ) improve bone structure premenopausal woman IOP .</brief_summary>
	<brief_title>Forteo Treatment Unexplained Osteoporosis Premenopausal Women</brief_title>
	<detailed_description>Idiopathic osteoporosis ( IOP ) uncommon disorder otherwise healthy young individual sustain one low-trauma fracture . In study IOP men , histomorphometric index bone formation depress , affect men respond PTH ( 1-34 ) robust increase lumbar spine ( LS ) bone mineral density ( BMD ) . We begin third year R01 ( AR4989603 ) investigate etiology pathogenesis , well histomorphometric bone microarchitectural feature IOP premenopausal woman . We find evidence markedly decrease bone formation microarchitectural deterioration decrease mechanical competence/strength . Teriparatide [ PTH ( 1-34 ) ] anabolic agent stimulate bone formation improve bone microarchitecture . Based upon finding , hypothesize teriparatide significantly increase BMD improve microarchitecture premenopausal woman IOP . We test hypothesis open-label study carefully characterize premenopausal woman IOP participate NIH-funded study fragility fracture low bone density . Participants study receive 18-24 month teriparatide effect BMD microstructure , bone mechanical competence , bone turnover assess . In order ass whether teriparatide stimulate bone formation extent woman IOP normal woman , compare short-term change ( 2 4 week ) biochemical marker bone formation response teriparatide woman IOP normal woman participate NIH-funded study control .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Premenopausal woman race Ages 20 48 Regular menses ( least 8 period last 12 month ) . FSH &lt; 20 mIU/ml early follicular phase , exclude woman perimenopause . Fracture subject : document low trauma fracture ( ) age &gt; = 18 ( e.g. , fracture associate fall stand height less ) . Low BMD subject : DXA BMD T score less equal 2.5 LS , total hip , femoral neck distal radius , fracture Control subject : DXA BMD T score great equal 1.0 LS , total hip , femoral neck distal radius , fracture . All subject must use appropriate birth control method prevent pregnancy duration teriparatide treatment . Secondary Causes Osteoporosis Disorders mineral metabolism : primary secondary hyperparathyroidism ( serum intact PTH &gt; 65 pg/ml ) , vitamin D deficiency ( serum 25OHD &lt; 30 ng/ml ) , hypercalciuria ( &gt; 300 mg/g creatinine ) , Paget 's disease , clinical osteomalacia , osteogenesis imperfecta ( OI ) . Recent pregnancy lactation ( within past year ) . Prolonged amenorrhea ( &gt; 6 month ) reproductive year ( except pregnancy lactation ) . History anorexia nervosa . Malignancy , except cure basal squamous cell skin carcinoma . Endocrinopathy : hyperthyroidism ( elevate serum thyroxine and/or suppress TSH ) , untreated hypothyroidism , Cushing 's syndrome , prolactinsecreting pituitary adenoma . Renal insufficiency ( serum creatinine upper limit female normal range ) . Liver disease ( AST , ALT , bilirubin , total alkaline phosphatase activity upper normal limit ) . Intestinal disorder ( celiac disease , pancreatic insufficiency , inflammatory bowel disease ) . History current use glucocorticoid , anticonvulsant , anticoagulant , diuretic , methotrexate . Current use depot preparation progesterone GnRH agonist . Current use drug therapy osteoporosis ( estrogen preparation contraceptive , raloxifene , bisphosphonates , calcitonin , PTH ) . Subjects agree discontinue use medication eligible participate 6 month discontinue raloxifene calcitonin , 12 month discontinue bisphosphonates . Total exposure bisphosphonates must &lt; 1 year . Subjects take PTH time past eligible . Additional contraindication teriparatide use : Unexplained elevate total bone specific alkaline phosphatase prior external beam implant radiation therapy involve skeleton .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Teriparatide</keyword>
	<keyword>Forteo</keyword>
	<keyword>Osteopenia</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Fracture</keyword>
	<keyword>Low Bone Density</keyword>
	<keyword>Premenopausal woman</keyword>
</DOC>